StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
AUPHAurinia Pharmaceuticals Inc.
stockpulse.co.kr
Nasdaq
$16.86▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.17BShares out 1.300M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

7
  • 9.11After-hours26.09.12 05:26
    4Ownership#●●●

    Aurinia Pharmaceuticals Inc.

    Aurinia Pharmaceuticals insider Stephen P. Robertson reported changes in beneficial ownership of securities effective September 10, 2026. This filing serves as a formal disclosure of the insider's updated equity holdings.…more

    $16.86+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 8.27Overnight26.08.27 10:24
    SCHEDULE 13D/AOwnership

    Aurinia Pharmaceuticals Inc.

    Key executives and affiliates of the ILJIN Group, including Tae Wan Kim, Sae Kyoung Huh, and Chin Kyu Huh, have been officially listed as reporting persons holding shares in Aurinia Pharmaceuticals. This Schedule 13D/A filing confirms their status as reporting persons associated with ILJIN SNT and ILJIN Steel.…more

    $16.86+0.00%vs prev close
    View filingShare
  • 8.26Overnight26.08.26 10:29
    4Ownership

    Aurinia Pharmaceuticals Inc.

    Aurinia Pharmaceuticals insider Stephen P. Robertson filed a Form 4 with the SEC on August 25, 2026, reporting changes in beneficial ownership of company securities that occurred on August 21, 2026. This filing serves as a standard disclosure of insider equity transactions.…more

    $16.86+0.00%vs prev close
    View filingShare

6 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 8.20Regular26.08.20 22:30
    Bullish#●●●#●●●

    Aurinia Settles Patent Dispute with Teva Over Kidney Disease Drug

    Aurinia Pharmaceuticals has reached a settlement with Teva, delaying the potential launch of a generic version of its drug Lupkynis until December 2036. This agreement secures the validity of Aurinia's patents, providing long-term protection for its core product.…more

    $16.86+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga
  • 8.19After-hours26.08.20 05:07

    ●●●●●●●● ●●●●● ●●●●●●

    Aurinia has reached a settlement with Teva to resolve patent litigation, effectively protecting its voclosporin exclusivity in the U.S. until December 2036. The agreement confirms the validity of key patents while the company continues legal actions against other generic competitors.…more

    $16.86+0.00%vs prev close
    ShareBenzinga

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →